FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Libreria Peptidica

Thymosin Alpha-1

Ta1 / Zadaxin / Thymalfasin

Immune & Thymic

Thymosin Alpha-1 (Ta1) is a 28-amino acid immunomodulatory peptide originally isolated from thymic tissue (thymosin fraction 5) by Allan Goldstein at George Washington University in the 1970s. It is approved in over 35 countries under the brand name Zadaxin for the treatment of chronic hepatitis B and C, and holds FDA orphan drug designation for hepatocellular carcinoma and DiGeorge syndrome. Ta1 acts as a pleiotropic immune modulator, enhancing dendritic cell maturation, T-cell differentiation, and NK cell cytotoxicity while simultaneously dampening excessive inflammatory responses.

Meccanismo d'azione

Naturally occurring 28-amino-acid thymic peptide that modulates T-cell maturation and function. Activates toll-like receptors (TLR2, TLR9), promotes dendritic cell maturation, enhances NK cell cytotoxicity, and shifts Th1/Th2 balance toward Th1-dominant immune responses.

Protocolli di ricerca

Solo per scopi di ricerca. Non è consiglio medico.

Research protocols use 1.6mg subcutaneously twice weekly. Hepatitis B/C protocols: 1.6mg twice weekly for 6-12 months. Immune support protocols: 1.6mg 2-3 times weekly for 2-4 weeks.

Note di ricerca

Clinical Research Status

Thymosin Alpha-1 (Zadaxin) is approved in 35+ countries including China, India, and throughout Southeast Asia and South America for hepatitis B and as an immune adjuvant. It holds FDA orphan drug designation for hepatocellular carcinoma, DiGeorge syndrome, and as an adjunct to influenza vaccine in immunocompromised patients, but has not achieved full FDA approval. Over 4,500 patients have been studied in controlled clinical trials spanning hepatitis, cancer immunotherapy, vaccine adjuvant therapy, and sepsis. Recent research has explored its use in severe COVID-19 infections, with retrospective studies showing reduced mortality in critically ill patients.

Key Published Findings

A meta-analysis of 7 randomized controlled trials published in the Journal of Viral Hepatitis showed Ta1 combined with interferon-alpha produced sustained virologic response rates of 50-55% in hepatitis B versus 25-30% for interferon alone. Studies in hepatocellular carcinoma patients demonstrated improved 12-month survival and reduced recurrence when Ta1 was used as adjuvant immunotherapy post-resection. A 2020 retrospective study in severe COVID-19 patients showed Ta1 treatment was associated with reduced mortality (11% vs 30%) and restoration of T-cell counts. Research demonstrates Ta1 activates toll-like receptors (TLR2, TLR9) on dendritic cells, bridging innate and adaptive immune responses.

Safety Profile

Thymosin Alpha-1 has one of the most extensive safety databases among peptide therapeutics, with over 20 years of clinical use across 35+ countries and 4,500+ trial participants. The most common adverse effect is mild injection site discomfort; no significant organ toxicity, autoimmune flares, or immunosuppression rebound has been documented. Unlike interferon or IL-2, Ta1 does not cause flu-like symptoms, myelosuppression, or the severe adverse effects associated with other immunomodulators. It modulates rather than simply stimulates immunity, which may explain the absence of cytokine storm risk even in inflammatory conditions.

Drug Interactions & Contraindications

Ta1 is synergistic with interferon-alpha and is commonly co-administered in hepatitis treatment protocols without adverse interactions. Theoretical caution applies in patients taking immunosuppressive drugs (tacrolimus, cyclosporine) for organ transplants, as Ta1 may counteract immunosuppression. Concurrent use with checkpoint inhibitors (anti-PD-1, anti-CTLA-4) is being studied and may enhance anti-tumor immunity but requires monitoring for immune-related adverse events. No absolute contraindications have been established, though it should be used cautiously in patients with active autoimmune diseases.

Comparison to Related Compounds

Unlike thymosin beta-4 (TB-500), which primarily promotes tissue repair and angiogenesis, Thymosin Alpha-1 is specifically an immune modulator with minimal tissue repair properties. Compared to interferon-alpha, Ta1 achieves similar or superior virologic responses in hepatitis with dramatically fewer side effects and better tolerability. Relative to other immune peptides like LL-37, Ta1 acts more on adaptive immunity (T-cells, dendritic cells) rather than innate antimicrobial defense. Its immunomodulatory (rather than immunostimulatory) profile distinguishes it from IL-2 and colony-stimulating factors, making it safer in inflammatory contexts.

Community Observations

Users typically dose Thymosin Alpha-1 at 1.6 mg subcutaneously, 2-3 times per week, mirroring the clinical trial protocols used for Zadaxin. Many report subjective improvements in recovery from illness, reduced frequency of infections, and improved response to vaccines. It is popular among immunocompromised individuals, those with chronic viral infections, and as part of integrative oncology protocols. The peptide is well-tolerated with virtually no reported adverse effects in community use, consistent with its extensive clinical safety data.

Semplifichro

~2 hours

Riconcimimento

Bacteriostatic water (BAC) or sterile water

Conservazione

Lyofilizzato

Refrigerate 2-8C up to 36 months.

Riconcimato

Refrigerate 2-8C. Use within 14 days.

Stato legale USA

FDA-approved orphan drug status; approved in 35+ countries

Anche noto come

Ta1ZadaxinThymalfasin

Domande frequenti

Che cos'è Thymosin Alpha-1?

Thymosin Alpha-1 (Ta1) is a 28-amino acid immunomodulatory peptide originally isolated from thymic tissue (thymosin fraction 5) by Allan Goldstein at George Washington University in the 1970s. It is approved in over 35 countries under the brand name Zadaxin for the treatment of chronic hepatitis B and C, and holds FDA orphan drug designation for hepatocellular carcinoma and DiGeorge syndrome. Ta1 acts as a pleiotropic immune modulator, enhancing dendritic cell maturation, T-cell differentiation, and NK cell cytotoxicity while simultaneously dampening excessive inflammatory responses.

Come agisce Thymosin Alpha-1?

Naturally occurring 28-amino-acid thymic peptide that modulates T-cell maturation and function. Activates toll-like receptors (TLR2, TLR9), promotes dendritic cell maturation, enhances NK cell cytotoxicity, and shifts Th1/Th2 balance toward Th1-dominant immune responses.

Qual è lo stato normativo di Thymosin Alpha-1 negli Stati Uniti?

FDA-approved orphan drug status; approved in 35+ countries

Qual è l'emivita di Thymosin Alpha-1?

~2 hours

Con quali altri nomi è noto Thymosin Alpha-1?

Ta1, Zadaxin, Thymalfasin

Peptide Contacts fornisce riassunti basati su ricerche a fini informativi soltanto. Non ospitiamo, distribuiamo o endossiamo le comunicazioni dei fornitori. Tutti i certificati di analisi, certificati GMP e comunicazioni del fornitore devono essere richiesti e verificati direttamente dall'acquirente. Niente su questa piattaforma costituisce consigli legali, medici o professionali. I utenti sono responsabili unicamente della verifica delle credenziali dei fornitori e dell'assicurazione del rispetto di tutte le leggi locali, regionali e federali applicabili prima di acquistare qualsiasi chimica di ricerca. L'uso di questa piattaforma costituisce l'accettazione piena della responsabilità personale.

Leggi l'intera dichiarazione di responsabilità